DNLI
Price
$14.70
Change
+$0.48 (+3.38%)
Updated
Jun 6 closing price
Capitalization
2.07B
53 days until earnings call
IDYA
Price
$21.73
Change
+$0.63 (+2.99%)
Updated
Jun 6 closing price
Capitalization
1.85B
65 days until earnings call
Interact to see
Advertisement

DNLI vs IDYA

Header iconDNLI vs IDYA Comparison
Open Charts DNLI vs IDYABanner chart's image
Denali Therapeutics
Price$14.70
Change+$0.48 (+3.38%)
Volume$1.79M
Capitalization2.07B
IDEAYA Biosciences
Price$21.73
Change+$0.63 (+2.99%)
Volume$789.21K
Capitalization1.85B
DNLI vs IDYA Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. IDYA commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and IDYA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (DNLI: $13.04 vs. IDYA: $19.56)
Brand notoriety: DNLI and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 82% vs. IDYA: 75%
Market capitalization -- DNLI: $2.07B vs. IDYA: $1.85B
DNLI [@Biotechnology] is valued at $2.07B. IDYA’s [@Biotechnology] market capitalization is $1.85B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 3 TA indicator(s) are bullish while IDYA’s TA Score has 6 bullish TA indicator(s).

  • DNLI’s TA Score: 3 bullish, 6 bearish.
  • IDYA’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -4.75% price change this week, while IDYA (@Biotechnology) price change was +2.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

IDYA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.07B) has a higher market cap than IDYA($1.85B). IDYA YTD gains are higher at: -23.891 vs. DNLI (-36.016). IDYA has higher annual earnings (EBITDA): -323.14M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. IDYA (676M). IDYA has less debt than DNLI: IDYA (19.2M) vs DNLI (48.7M). IDYA has higher revenues than DNLI: IDYA (7M) vs DNLI (0).
DNLIIDYADNLI / IDYA
Capitalization2.07B1.85B112%
EBITDA-492.89M-323.14M153%
Gain YTD-36.016-23.891151%
P/E RatioN/AN/A-
Revenue07M-
Total Cash832M676M123%
Total Debt48.7M19.2M254%
FUNDAMENTALS RATINGS
DNLI vs IDYA: Fundamental Ratings
DNLI
IDYA
OUTLOOK RATING
1..100
6519
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
61
Fair valued
PROFIT vs RISK RATING
1..100
10065
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
9063
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
8595

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (61) in the null industry is in the same range as DNLI (93) in the Biotechnology industry. This means that IDYA’s stock grew similarly to DNLI’s over the last 12 months.

IDYA's Profit vs Risk Rating (65) in the null industry is somewhat better than the same rating for DNLI (100) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than DNLI’s over the last 12 months.

IDYA's SMR Rating (95) in the null industry is in the same range as DNLI (95) in the Biotechnology industry. This means that IDYA’s stock grew similarly to DNLI’s over the last 12 months.

IDYA's Price Growth Rating (63) in the null industry is in the same range as DNLI (90) in the Biotechnology industry. This means that IDYA’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that DNLI’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIIDYA
RSI
ODDS (%)
Bearish Trend 11 days ago
89%
Bearish Trend 11 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 11 days ago
75%
Bearish Trend 11 days ago
85%
Momentum
ODDS (%)
Bearish Trend 11 days ago
81%
Bullish Trend 11 days ago
77%
MACD
ODDS (%)
Bearish Trend 11 days ago
76%
Bullish Trend 11 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 11 days ago
83%
Bearish Trend 11 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
85%
Bullish Trend 11 days ago
80%
Advances
ODDS (%)
Bullish Trend 19 days ago
78%
Bullish Trend 11 days ago
76%
Declines
ODDS (%)
Bearish Trend 11 days ago
80%
Bearish Trend 17 days ago
77%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 11 days ago
69%
Bullish Trend 11 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-1.29%
BEAM - DNLI
61%
Loosely correlated
-0.88%
RCKT - DNLI
59%
Loosely correlated
+6.44%
NTLA - DNLI
59%
Loosely correlated
+3.59%
ARWR - DNLI
58%
Loosely correlated
+1.24%
RGNX - DNLI
58%
Loosely correlated
-5.84%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+0.72%
IMNM - IDYA
59%
Loosely correlated
+0.35%
CGON - IDYA
58%
Loosely correlated
-0.94%
NTLA - IDYA
57%
Loosely correlated
+3.59%
DNLI - IDYA
56%
Loosely correlated
-1.29%
CRNX - IDYA
56%
Loosely correlated
+1.39%
More